**Artesunate reduces cell growth and induces ferroptosis in therapy-resistant renal cell carcinoma cells**

By: Juengel E.\(^1\), Markowitsch S.\(^1\), Schupp P.\(^1\), Schunke J.\(^1\), Efferth T.\(^2\), Mager R.\(^1\), Haferkamp A.\(^1\)

\(^1\)Mainz University Medical Center, Johannes Gutenberg University Mainz, Department of Urology and Pediatric Urology, Mainz, Germany, \(^2\)Institute of Pharmacy and Biochemistry, Johannes Gutenberg University Mainz, Department of Pharmaceutical Biology, Mainz, Germany

**225Ac-labeled girentuximab for targeted alpha therapy of CAIX-expressing renal cell cancer xenografts**

By: Oosterwijk E.\(^1\), Merkx R.\(^1\), Kip A.\(^2\), Morgenstern A.\(^3\), Bruchertseifer F.\(^3\), Rijpkema M.\(^2\), Mulders P.F.A.\(^1\), Heskamp S.\(^2\)

\(^1\)Radboudumc, Urology, Nijmegen, The Netherlands, \(^2\)Radboudumc, Radiology, Nijmegen, The Netherlands, \(^3\)Joint Research Center, European Commission, Brussels, Belgium

**Clinical activity of vofatamab, an FGFR3 selective antibody in combination with pembrolizumab in metastatic urothelial carcinoma (mUC), updated follow up results from the interim analysis of FIERCE-22**

By: Siefker-Radtke A.\(^1\), Lugowska I.\(^2\), Tupikowski K.\(^3\), Andric Z.\(^4\), Rezazadeh-Kalebasty A.\(^5\), Curigliano G.\(^6\), Vaena D.\(^7\), Vogl F.D.\(^8\), Currie G.\(^8\), Abella E.\(^8\), Kelly W.\(^9\)

\(^1\)MD Anderson Cancer Center, Dept of Genitourinary Medical Oncology, Houston, United States of America, \(^2\)Oncology Center, Dept of Soft Tissue/Bone Sarcoma and Melanoma, Warsaw, Poland, \(^3\)Dolnoslaskie Oncology Center, Dept of Urology, Wroclaw, Poland, \(^4\)Clinical Hospital Center Bezanjska Kosa, Medical Oncology, Belgrade, Serbia, \(^5\)Norton Cancer Institute, Oncology, Louisville, KY, United States of America, \(^6\)European Institute of Oncology, Division of Early Drug Development, Milan, Italy, \(^7\)The West Clinic, Medical Oncology, Germantown, TN, United States of America, \(^8\)Rainier Therapeutics, Inc, San Leandro, United States of America, \(^9\)Thomas Jefferson University Hospital, Division of Solid Tumor Oncology, Philadelphia, PA, United States of America
Preliminary proteomic analysis of F.F.P.E. tumor samples for predicting the response of bladder cancer patients to anti-PD-1/PDL-1 therapy


1 Biomedical Research Foundation Academy of Athens, Proteomics Laboratory, Biotechnology Division, Athens, Greece, 2 National & Kapodistrian University of Athens, Pathology Department, Athens, Greece, 3 National & Kapodistrian University of Athens, Department of Clinical Therapeutics, Athens, Greece, 4 Benaki Phytopathological Institute, Laboratory of Toxicological Control of Pesticides, Department of Pesticides Control and Phytopharmacy, Athens, Greece